Elanco Animal Health (NYSE:ELAN) Issues FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.800-0.860 for the period, compared to the consensus EPS estimate of 0.900. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its FY25 guidance to $0.80-$0.86 EPS.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded down $0.48 during trading hours on Tuesday, hitting $10.64. The company’s stock had a trading volume of 5,715,426 shares, compared to its average volume of 4,694,626. The company has a market cap of $5.26 billion, a PE ratio of 26.58, a PEG ratio of 2.50 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The business has a 50 day moving average price of $11.78 and a two-hundred day moving average price of $13.09. Elanco Animal Health has a 12-month low of $10.20 and a 12-month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the firm posted $0.08 earnings per share. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. Analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

ELAN has been the topic of several analyst reports. Morgan Stanley reduced their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. UBS Group assumed coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price target on the stock. Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Finally, Barclays lifted their target price on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health currently has an average rating of “Hold” and an average price target of $16.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.